Ayala Pharmaceuticals (NASDAQ:ADXS) Receives New Coverage from Analysts at StockNews.com

Investment analysts at StockNews.com started coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a report released on Wednesday. The brokerage set a “sell” rating on the stock.

Ayala Pharmaceuticals Stock Performance

Shares of ADXS opened at $0.02 on Wednesday. The company has a 50-day simple moving average of $0.16 and a 200-day simple moving average of $0.45. Ayala Pharmaceuticals has a 52 week low of $0.00 and a 52 week high of $1.49. The firm has a market capitalization of $852,660.00, a P/E ratio of 0.00 and a beta of 1.56.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.